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788Objectives: This retrospective, multicenter study aimed to determine prognostic factors of completely resected
pathologic N2 stage IIIA non–small cell cancer (NSCLC).
Methods: From 25 participating hospitals, 496 patients (325 men and 171 women; median age, 65 years) who
underwent complete resection without preoperative treatment for pT1-3 N2 M0, stage IIIA NSCLC be-
tween 2000 and 2004 were enrolled. Lobectomy/bilobectomy was performed in 462 patients and pneumonec-
tomy in 34. Some kind of adjuvant chemotherapy was administered to 296 patients. Survivals were calculated
using the Kaplan-Meier method, and prognostic factors were determined using the Cox proportional hazards
model.
Results: Five-year overall survival (OS) and disease-free survival (DFS) were 44.8% and 24.2%, respectively.
pT classification (hazard ratio (HR), pT1/pT2/pT3¼ 1/1.32/2.03), single or multiple N2 metastases (HR, single/
multiple ¼ 1/1.36), and skip or nonskip N2 metastasis (HR, skip/nonskip ¼ 1/1.30) were found to be indepen-
dent prognostic factors for DFS. Sex (HR, female/male¼ 1/1.36), performance status (HR, PS-0/PS-1¼ 1/1.37),
tumor diameter (HR, 1.12 per 1-cm increase), pT-factor (HR, pT1/pT2/pT3 ¼ 1/1.37/2.22), and extent of N2
metastasis (HR, localized/extended ¼ 1/1.39) were shown to be independent prognostic factors for OS.
Conclusions: We found that pT classification was a significant prognostic indicator for OS and DFS whereas
tumor diameter, performance status, and sex were ones for OS. Single N2 metastasis and skip N2 metastasis
were demonstrated as favorable prognostic factors for DFS, limited N2 metastasis was one for OS, and these
should be considered as stratification factors for trial on adjuvant therapy. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and Cardiovascular SurgThe prognosis of completely resected pathologic (p) N2
stage IIIA non–small cell lung cancer (NSCLC) is still un-
satisfactory owing to a high incidence of metastasis or tu-
mor recurrence.1 A meta-analysis on cisplatin-based
adjuvant chemotherapy after initial resection has shown
that it improves survival.2 However, the efficacy of adjuvant
chemotherapy in Japanese phase III trials has been contro-
versial.3,4 Therefore, several phase II and III trials on
adjuvant chemotherapy have been planned in Japan.
It is widely known that the prognosis of pN2 stage IIIA
NSCLC is heterogeneous, and T and clinical (c) N classifi-
cations have been identified as prognostic factors.5 These
factors are considered as stratification criteria in clinical tri-
als. Although pattern of metastasis to N2 regions has also
been reported as a prognostic factor.5,6 Its influence on
adjuvant chemotherapy has not yet been clarified; thus, it
is not considered as stratification criteria in clinical trials
of adjuvant chemotherapy for patients with pN2 stage
IIIA NSCLC.
In this study, we retrospectively investigated the outcome
of patients with completely resected pN2 stage IIIA
NSCLC, who were treated at institutions participating inery c October 2013
Abbreviations and Acronyms
c ¼ clinical
DFS ¼ disease-free survival
ECOG ¼ Eastern Cooperative Oncology Group
EGFR ¼ epidermal growth factor receptor
HR ¼ hazard ratio
IV-CT ¼ intravenous chemotherapy
JMTO ¼ Japan-Multinational Trial Organization
NSCLC ¼ non–small cell lung cancer
OS ¼ operative survival
p ¼ pathologic
PS ¼ performance status
UFT ¼ tegafur-uracil
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tion (JMTO) to determine prognostic factors, particularly
prognostic value of pattern of metastasis to N2 regions
and adjuvant chemotherapy.
PATIENTS AND METHODS
Study Design
In this retrospective study, 25 institutions affiliated with the JMTO
(listed in the Acknowledgements section) recruited patients who met the
eligibility criteria, which began in January 2008, and all data including
follow-up information until either death or December 2010 were
assessed in April 2011.
Eligibility Criteria
Patients with NSCLC who had undergone complete resection by lobec-
tomy, bilobectomy, or pneumonectomy with at least standard ipsilateral hi-
lar/mediastinal lymph node dissection (defined by the General Rule for
Clinical and Pathological Record of Lung Cancer7) between January
2000 and December 2004, and whose tumors were pathologically proven
T1-3 N2 M0, stage IIIA according to the sixth edition of the International
System for Staging Lung Cancer,8 were eligible. The eligibility criteria in-
cluded the following: no chemotherapy or radiotherapy before surgery;
older than 20 years of age; Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0 or 1; and written informed consent
for surgical resection. Patients were excluded if they had 1 or more of
the following factors: active double cancer; serious infections; cardiac, he-
patic, renal, or psychologic diseases at the time of lung resection; history of
preoperative treatment with chemotherapy or radiotherapy; and intraoper-
ative anticancer drug administration in the thorax or pericardium. Patients
who underwent sublobar resection such as segmentectomy for their
NSCLCwere also excluded. The study protocol was approved by the ethics
committee of JMTO (JMTO LC 05-01 study) and the institutional ethics
committee of each participating institution. From 25 institutions, 512 pa-
tients were recruited. Of these, 12 patients received sublobar resection
and 4 patients received insufficient lymph node dissection. Finally, 496 pa-
tients were eligible in the study (Figure 1). Their characteristics are shown
in Table 1. Of these, 2 (0.4%) patients died of postoperative complication
within 30 days after surgery.
Adjuvant Therapy and Follow-up
In the period between January 2000 and December 2004, the signifi-
cance of induction treatment, adjuvant chemotherapy, or adjuvant radio-
therapy was not established. Therefore, indications for resection for cN2The Journal of Thoracic and Cadisease and postoperative chemotherapy and/or radiotherapy were depen-
dent on each institution. As adjuvant chemotherapy, oral tegafur-uracil
(UFT) or intravenous chemotherapy (IV-CT) was selected. IV-CT regimens
that were used included carboplatin and paclitaxel, cisplatin and docetaxel,
cisplatin or carboplatin and gemcitabine, cisplatin and 5-fluorouracil, and
a combination of cisplatin, mitomycin C, and vindesine. As adjuvant radio-
therapy, irradiation with 50 to 60 Gy to hilar and mediastinal areas was per-
formed. Of 496 patients, 122 (24.6%) received IV-CT, 89 (17.9%)
received IV-CTand radiotherapy, 60 (12.1%) received UFT, 25 (5.0%) re-
ceived UFT and radiotherapy, 49 (9.9%) received radiotherapy, and 151
(30.4%) did not receive adjuvant therapy.
The follow-up examination schedule was arranged by each individual
institution; most of the patients received medical check-ups and chest
x-ray films at least twice per year.
Data Collection
The collected data included age, sex, ECOG PS, cT and cN classifica-
tions, affected lobe of lung, operation date, operation mode, pT classifica-
tion, maximum tumor size (centimeters), tumor histology in accordance
with the World Health Organization classification,9 station of node(s)
with metastasis, adjuvant chemotherapy, adjuvant radiation therapy, pres-
ence or absence of recurrent tumor, date of diagnosis of recurrent tumor,
and follow-up information until either death or December 2010. These
data were obtained from the inpatient and outpatient medical records and
imaging tests. These data were accumulated through a web-based registra-
tion system established by JMTO.
Patterns of Metastasis to N2 Regions
Metastasis to the N2 regions was classified as follows: (1) single (metas-
tasis to 1 N2 station) or multiple (metastases to 2 or more N2 stations) N2
metastases; (2) skip (no metastasis to the N1 region) or nonskip (metastasis
to the N1 region) N2 metastases; and (3) extent of N2 stations with metas-
tasis, defined as localized or extended N2 metastasis. ‘‘Localized N2 me-
tastasis’’ was defined as metastatic spread of the tumor to right #1, right
#2, #3, and/or right #4 N2 station(s) of the right upper lobe; left #1, left
#2, #3, left #4, #5, and/or #6 N2 station(s) of the left upper lobe; right
#1, right #2, #3, right #4, and/or #7 N2 station(s) of the right middle
lobe; #7, right #8, and/or right #9 N2 station(s) of the right lower lobe,
and #7, left #8, and/or left #9 N2 station(s) of the left lower lobe. ‘‘Extended
N2 metastasis’’ was defined as metastasic spread of the tumor to #7, ipsi-
lateral #8, and/or ipsilateral #9 N2 station(s) of the upper lobe; right #8
and/or right #9 N2 station(s) in the right middle lobe; ipsilateral #1, #2,
#3, and/or #4 N2 station(s) in the right lower lobe; and ipsilateral #1, #2,
#3, #4, #5, and/or #6 N2 station(s) in the left lower lobe. Under these clas-
sifications, 294 (59.3%) patients had single N2 metastasis and 202
(40.7%) had multiple N2 metastasis. An equal frequency of skip and non-
skip N2 metastases was observed; both were found in 248 (50.0%) pa-
tients. The number of patients with skip N2 metastasis by primary tumor
location was 89 (50.3%) of 177 in the right upper lobe, 10 (40.0%) of
25 in the right middle lobe, 57 (47.5%) of 120 in the right lower lobe,
63 (57.3%) of 110 in the left upper lobe, and 29 (45.3%) of 64 in the
left lower lobe. Localized N2metastases were observed in 369 (74.4%) pa-
tients, and extendedN2metastases were in 127 (25.6%) patients. The num-
ber of patients with extended N2 metastasis by primary tumor location was
34 (19.2%) of 177 in the right upper lobe, 0 (0%) of 25 in the right middle
lobe, 50 (41.7%) of 120 in the right lower lobe, 14 (12.7%) of 110 in the
left upper lobe, and 29 (45.3%) of 64 in left lower lobe.Statistical Considerations
Categorical data were examined using the c2 test. Prognostic evaluation
was performed by consideration of the disease-free survival (DFS) and over-
all survival (OS). DFS was defined as time to lung cancer recurrence or
non–lung cancer death. The impact of the following clinical-pathologicrdiovascular Surgery c Volume 146, Number 4 789
TABLE 1. Patient characteristics
Variables No. of patients (%)
Age (y) Mean 65.0
60 152 (30.6%)
61-70 175 (35.3%)
>71 169 (34.1%)
Sex
Female 171 (34.5%)
Male 325 (65.5%)
ECOG performance status
PS 0 404 (81.5%)
PS 1 92 (18.5%)
Clinical T classification
cT1 204 (41.1%)
cT2 251 (50.6%)
cT3/4 41 (8.3%)
Clinical N classification
cN0 311 (62.7%)
cN1 62 (12.5%)
cN2/3 123 (24.8%)
Clinical stage
Stage I 295 (59.5%)
Stage II 69 (13.9%)
Stage III 132 (26.6%)
Tumor location
Right 322 (64.9%)
Left 174 (35.1%)
Types of resection
Lobectomy 448 (90.3%)
Sleeve lobectomy 12 (2.4%)
Bilobectomy 2 (0.4%)
Pneumonectomy 34 (6.9%)
Pathologic T classification
pT1 191 (38.5%)
pT2 256 (51.6%)
pT3 49 (9.9%)
Tumor histology
Adenocarcinoma 357 (72.0%)
Squamous cell carcinoma 110 (22.2%)
Large cell carcinoma 17 (3.4%)
Adenosquamous cell carcinoma 12 (2.4%)
Adjuvant therapy
None 151 (30.4%)
Intravenous chemotherapy 122 (24.6%)
Intravenous chemotherapy þ radiation 89 (17.9%)
Oral tegafur and uracil 60 (12.1%)
Oral tegafur and uracil þ radiotherapy 25 (5.0%)
Radiotherapy 49 (9.9%)
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
FIGURE 1. Patient selection. From 25 institutions, 512 patients who
potentially met the study criteria were recruited. Assessment of collected
data revealed that 12 patients received sublobar resection and 4 patients
received insufficient lymph node dissection. Finally, 496 patients were
eligible in the study.
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sex, ECOGPS (PS 0 vs PS 1), tumor size inmaximal diameter (centimeters),
cT classification, cN classification, tumor location (right vs left), operation
mode (pneumonectomy vs lobectomy including bilobectomy and sleeve lo-
bectomy), tumor histology (adenocarcinoma, squamous cell carcinoma,
large cell carcinoma, or adenosquamous cell carcinoma), pT classification,
adjuvant chemotherapy (none,UFT, or IV-CT for simplification purposes in-
asmuch as a wide range of intravenous chemotherapy regimens were used),
adjuvant radiation therapy, single ormultipleN2metastases, skip or nonskip
N2 metastasis, and localized or extended N2 metastasis. Survival curves
were calculated using the Kaplan-Meier method and compared using the
log-rank test. To evaluate the prognostic effect of IV-CT compared with sur-
gery alone, we matched patients on the basis of propensity score. The pro-
pensity score for IV-CT was constructed using binary logistic regression
including patients’ age, sex, ECOG PS, tumor histology, pT classification,
operation mode, single or multiple N2 metastases, skip or nonskip N2
metastasis, and localized or extended N2 metastasis. Nearest neighbor
matching with a caliper of .005 difference was used to match 128 patients
with IV-CTand 128 patients without no adjuvant chemotherapy. Regarding
pT classification and pattern of metastasis to N2 region, 5-year DFSs on the
basis of IV-CT and radiotherapy were calculated. When significant
(P value<.05) and borderline (P value<.10) variables under this univariate
method showed linearity and time dependency, they were tested with a mul-
tivariate analysis using the Cox proportional hazards model. JMP software
version 9.03 (SAS Institute, Inc, Cary, NC) was used to carry out all statis-
tical calculations. All statistical tests were 2-sided. Our statistician (S.T.)
reviewed the statistical methods.RESULTS
Survival Analyses
Themedian follow-up period was 57 months. Recurrence
occurred in 342 patients during the follow-up period, and of790 The Journal of Thoracic and Cardiovascular Surgthese, 253 patients died of recurrent tumors whereas 89 pa-
tients were alive with recurrent tumors. Treatments after re-
currence were given according to each institutional
protocol. Thirty-six patients died of non–lung cancer–re-
lated causes, and 118 patients were alive without tumor re-
currence. The 3- and 5-year OSs were 59.5% and 44.8%,ery c October 2013
TABLE 2. Univariate analyses of prognostic factors for OS and DFS
Factors Variables Five-year OS (%) P value Five-year DFS (%) P value
Age 60 46.2 22.6
61-70 50.2 .9377 25.1 .8889
>71 37.5 .0329 24.8 .6914
Sex Female 53.8 24.1
Male 40.1 .0081 24.3 .6939
ECOG performance status PS 0 47.1 25.5
PS 1 34.1 .0061 18.1 .1823
Maximum tumor diameter By 1 cm increase — <.0001 — .0001
Clinical T classification cT1 54.2 29.8
cT2 41.1 .0019 21.6 .0370
cT3/4 21.6 <.0001 12.7 .0006
Clinical N classification cN0 48.7 25.2
cN1 41.3 .2275 23.8 .6084
cN2/3 36.6 .0095 22.1 .2978
Tumor location Right 42.3 24.0
Left 49.2 .2125 24.6 .6077
Types of resection Lobectomy* 46.5 25.2
Pneumonectomy 20.1 .0011 11.8 .0142
Pathologic T classification pT1 58.3 33.1
pT2 40.3 <.0001 20.1 .0016
pT3 14.1 <.0001 11.1 <.0001
Tumor histology Adenocarcinoma 58.3 21.8
Squamous cell ca. 42.4 .1587 30.3 .4844
Large cell ca. 35.3 .4026 29.4 .7746
Adenosquamous cell ca. 46.7 .9827 33.3 .8825
Adjuvant chemotherapy None 41.0 22.2
Intravenous chemotherapy 46.9 .0743 26.6 .0497
Oral tegafur and uracil 48.2 .1124 23.3 .4579
Adjuvant radiotherapy None 45.0 26.5
Mediastinal irradiation 44.3 .9041 19.6 .3846
Single or multiple N2 metastases Single 49.4 30.9
Multiple 38.6 .0291 14.8 .0002
Skip N2 metastasis Skip 47.8 29.4
Nonskip 41.7 .1680 19.0 .0071
Extent of N2 metastasis Localized 48.6 27.5
Extended 34.1 .0047 14.9 .0074
OS, Overall survival; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; ca, carcinoma; PS, performance status. *Lobectomy included lobectomy, bi-
lobectomy, and lobectomy with bronchoplasty.
Sonobe et al General Thoracic Surgery
G
T
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24.2%, respectively.
Univariate analysis for OS indicated that increased age,
male sex, ECOG PS 1, increasing cT classification, increas-
ing cN classification, pneumonectomy, increasing maxi-
mum tumor diameter, increasing pT classification,
multiple N2 metastases, and extended N2 metastasis were
significantly associated with poor OS (Table 2). Univariate
analysis also revealed that increasing cT classification,
pneumonectomy, increasing maximum tumor diameter, in-
creasing pT classification, multiple N2 metastases, nonskip
N2 metastasis, and extended N2 metastasis were signifi-
cantly associated with poor DFS (Table 2, Figure 2, A and
B). IV-CT had a marginal prognostic advantage on OS
and DFS as compared with no adjuvant chemotherapyThe Journal of Thoracic and Caalthough UFT or adjuvant radiotherapy did not (Table 2).
In the IV-CT group (n ¼ 211), 5-year OS and DFS of pa-
tients with radiotherapy (n ¼ 89) were 44.8% and 22.1%,
respectively, and were not different from 5-year OS
(48.4%) and DFS (29.7%) of those without radiotherapy
(n ¼ 122). In 128 matched pairs of patients by propensity
score, however, IV-CT had no prognostic advantage on
OS and DFS (Figure 2, C and D).
By multivariate analysis, sex, ECOG PS, maximum tu-
mor diameter, pT classification, and extent of N2 metastasis
were revealed to be independent prognostic factors affect-
ing OS (Table 3). Meanwhile, pT classification, single or
multiple N2 metastases, and skip or nonskip N2 metastasis
were demonstrated to be important prognostic factors for
DFS (Table 3).rdiovascular Surgery c Volume 146, Number 4 791
FIGURE 2. A, Disease-free survival according to single or multiple N2 metastases. Disease-free survival was significantly better in the single N2 metas-
tasis group than in the multiple N2metastases group (P¼ .0002, log-rank test). B, Disease-free survival according to skip or nonskip N2metastasis. Disease-
free survival was significantly better in the skip N2metastasis group than in the nonskip N2metastasis group (P¼ .0071, log-rank test). C, Propensity score–
adjusted overall survival according to intravenous chemotherapy. There was no difference between the intravenous chemotherapy group and surgery alone
group (P ¼ .4583, log-rank test). D, Propensity score–adjusted disease-free survival according to intravenous chemotherapy. There was no difference be-
tween the intravenous chemotherapy group and surgery alone group (P ¼ .8611, log-rank test).
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Pattern of Metastasis to N2 Regions
Because only IV-CT had a potential prognostic advan-
tage, survival of patients with IV-CT (n ¼ 122) or IV-CT
and radiotherapy (n ¼ 89) was compared with that of those
with surgery alone (n ¼ 151) according to pT classification
and pattern of metastasis to N2 regions. There were no dif-
ferences of DFS and OS among IV-CT, IV-CTand radiation,
and no adjuvant therapy groups according to pT classifica-
tion, single or multiple N2 metastases, or extent of N2
stations with metastasis. In the skip N2 metastasis group,
5-year DFSs were 44.9% in patients receiving IV-CT
(n ¼ 49), 28.7% in patients receiving IV-CT and radiother-
apy (n ¼ 46), and 26.1% in patients without adjuvant ther-
apy (n ¼ 68), and an effect of IV-CT on DFS was observed
(P¼ .0167, log-rank test). However, in the nonskip N2 me-
tastasis group, 5-year DFSs were 19.3% in patients receiv-
ing IV-CT (n¼ 79), 15.5% in patients receiving IV-CTand
radiotherapy (n ¼ 43), and 21.8% in patients without adju-
vant therapy (n ¼ 72), with no observed differences among
them (P ¼ .9970, log-rank test). The percentage of patients
receiving adjuvant IV-CT or IV-CT and radiotherapy was
not different among the pT classification groups
(P ¼ .5071, c2 test), and not different between single N2
metastasis and multiple N2 metastases groups (P ¼ .5312,792 The Journal of Thoracic and Cardiovascular Surgc2 test), skip or nonskip N2 metastasis (P ¼.2344, c2
test), or extent of N2 stations with metastasis (P ¼ .1184,
c2 test).
DISCUSSION
The 5-year OS in the study was 44.8% and was higher
than that reported by Goldstraw and associates10 (24%) un-
der a median follow-up period of 57 months. In our cohort,
89 patients were alive at the end of the study (December
2010), and they provided a higher OS than DFS. This
may be due to the exclusion of patients with comorbidity,
successful treatment for recurrent diseases including che-
motherapy, radiotherapy, and/or molecular targeting
drugs,11 and high percentage of tumors with mutations in
the epidermal growth factor receptor (EGFR) gene in Ja-
pan,12-14 which could be a better prognostic factor after
recurrence.14
We found that pT classification was a strong independent
prognostic factor for OS and DFS in patients with com-
pletely resected pN2 stage IIIA NSCLC. Increased pT clas-
sification signifies enhanced tumor invasiveness and/or
tumor burden. Several studies in Japan also showed a prog-
nostic significance of pT classification in cases of com-
pletely resected pN2 NSCLC,5,6,15 and our findings are
highly corroborative with theirs.ery c October 2013
TABLE 3. Multivariate analyses of prognostic factors for OS and DFS
Factors for overall survival Variables Hazard ratio (95% CI) P value
Age 60 1
61-70 0.86 (0.63-1.18) .3401
>71 1.19 (0.87-1.62) .2760
Sex Female 1
Male 1.35 (1.05-1.75) .0190
ECOG Performance status PS 0 1
PS 1 1.38 (1.02-1.85) .0395
Maximum tumor diameter (cm) By 1 cm increase 1.12 (1.02-1.22) .0159
Clinical T classification cT1 1
cT2 0.96 (0.67-1.38) .8392
cT3/4 1.29 (0.73-2.23) .3804
Clinical N classification cN0 1
cN1 0.94 (0.64-1.36) .7608
cN2/3 1.00 (0.74-1.34) .9929
Types of resection Lobectomy* 1
Pneumonectomy 1.47 (0.93-2.23) .0950
Pathologic T classification pT1 1
pT2 1.36 (0.95-1.94) .0954
pT3 2.09 (1.22-3.51) .0075
Adjuvant chemotherapy None 1
Intravenous chemotherapy 0.79 (0.61-1.03) .0821
Oral tegafur and uracil 0.80 (0.56-1.13) .2153
Single or multiple N2 metastases Single 1
Multiple 1.21 (0.94-1.56) .1335
Extent of N2 metastasis Localized 1
Extended 1.40 (1.06-1.84) .0184
Factors for disease-free survival Variables Hazard ratio (95% CI) P value
Maximum tumor diameter (cm) By 1-cm increase 1.05 (0.96-1.14) .3037
Clinical T classification cT1 1
cT2 0.95 (0.71-1.28) .7564
cT3/4 1.14 (0.69-1.85) .6024
Types of resection Lobectomy* 1
Pneumonectomy 1.40 (0.92-2.05) .1144
Pathologic T classification pT1 1
pT2 1.30 (0.96-1.76) .0927
pT3 2.02 (1.26-3.16) .0038
Adjuvant chemotherapy None 1
Intravenous chemotherapy 0.80 (0.64-1.01) .0588
Oral tegafur and uracil 1.02 (0.75-1.36) .9211
Single or multiple N2 metastases Single 1
Multiple 1.37 (1.10-1.71) .0049
Skip N2 metastasis Skip 1
Nonskip 1.31 (1.06-1.62) .0109
Extent of N2 metastasis Localized 1
Extended 1.14 (0.89-1.46) .2878
OS, Overall survival; DFS, disease-free survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status. *Lobectomy included lobec-
tomy, bilobectomy, and lobectomy with bronchoplasty.
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pendent prognostic factor affecting OS in our study. Okada
and associates16 reported that survival was prolonged in pa-
tients in whom mediastinal lymph node metastasis was lim-
ited to the upper mediastinal nodes from upper lobe tumors
or to lower mediastinal nodes from lower lobe tumors.The Journal of Thoracic and CaUehara and colleagues17 also reported that metastasis to up-
permediastinal lymph nodes from lower lobe tumorswas in-
dicative of a poor prognosis. These reports imply that
patients with localized N2metastasis as defined in our study
had better OS than did those with extended N2 metastasis.
In patients with extended N2 metastasis, tumor cellsrdiovascular Surgery c Volume 146, Number 4 793
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or through atypical lymphatic drainage routes; thus, the can-
cer cells may have strong metastatic potential leading to
a poor prognosis. Our findings also showed that single N2
metastasis and skip N2 metastasis are better independent
prognostic factors for DFS. The finding of better DFS in
patients with single N2 metastasis corroborated previous
studies that reported that the number of N2 stations withme-
tastasis was a good indicator for prognosis of completely re-
sected N2 NSCLC.5,18-22 Involvement of multiple N2
stations implies increased tumor burden in the lymphatic
flow and opportunity of systemic spread of tumor cells,
which can lead to early recurrence of tumors. Skip N2
metastasis is discontinuous spread of tumors to
mediastinal lymph nodes without involvement of the hilar
lymph nodes. The incidence of lymph node skipping
has been reported to be approximately 30%
(22%-50%),5,6,15,17-21,23 and that of our study (50.0%)
was slightly higher than these previous reports, which was
likely due to a bias resulting from the fact that 60% of our
patients had cN0 tumors. Several studies have reported
that patients with skip N2 metastasis showed better
prognosis than those with nonskip N2 metastasis5,6,15,19;
however, other reports with contradictory findings also
exist.20,21 In tumors with skip N2 metastasis, the total
number of lymph nodes involved in tumor metastasis to
both N1 and N2 stations is usually less than in those with
nonskip N2 metastasis. Therefore, inasmuch as the total
tumor burden in the lymphatic flow in skip N2 metastasis
is presumed to be smaller than in nonskip N2 metastasis,
this may lead to better DFS.22 In patients with skip N2 me-
tastasis and who received adjuvant IV-CT, better DFS was
observed, although DFS with regard to adjuvant chemother-
apywas not affected by single ormultipleN2metastases and
extent of N2 metastasis. The effect of adjuvant chemother-
apy on the basis of pattern of metastasis to N2 regions re-
mains unclear. Our data indicate that adjuvant IV-CT may
be more effective in patients with smaller tumor burden in
the lymphatic flow. In clinical trials of adjuvant chemother-
apy for N2 NSCLC, pattern of metastasis to N2 regions
should be taken into consideration as part of the stratification
criteria of patients for further investigation.
Sex and ECOG PS were demonstrated to be independent
prognostic factors for OS, but not for DFS. Female patients
may gain more benefit from treatment with tyrosine kinase
inhibitors for EGFR because many adenocarcinomas in fe-
male nonsmoker patients harbor EGFR gene muta-
tions.12-14 Further, patients with PS 0 can receive more
intensive and long-lasting chemotherapy than those with
PS 1 after recurrence. Clearly, these endogenous factors
have a great influence on OS. However, tumor recurrence
depends strongly on biological features of the tumor itself
and is largely independent of patient-specific factors such
as age, sex, or PS.794 The Journal of Thoracic and Cardiovascular SurgIn our report, 123 patients were clinically classified as
having N2 or N3 (cN2/3) disease and were diagnosed
with pN2 NSCLC. This subset of patients had a 5-year
OS of 36.6% with surgery alone (n ¼ 58; 5-year OS,
31.8%) or with surgery and adjuvant chemotherapy
(n ¼ 65; 5-year OS, 40.8%) and are currently considered
ideal for induction chemoradiotherapy followed by surgery
in the clinical trial setting.24 Because patients who were not
suitable for initial complete resection might have been
excluded in the study, a simple comparison between our re-
sults on cN2/pN2 patients and trials on induction chemora-
diotherapy would not be valid. However, in some trials on
induction chemoradiotherapy followed by surgery, the
lung cancer was considered to be potentially technically re-
sectable25; thus, findings from future clinical trials on in-
duction chemoradiotherapy followed by surgery for
pathologically proven cN2 stage IIIA NSCLC can be noted
and compared with our OS results for validation.
This study has several limitations owing to the retrospec-
tive aspect of the research. Tumors of enrolled patients were
evaluated as resectable without induction treatment, which
may represent a bias toward good prognosis. Survival ben-
efit of adjuvant chemotherapy or chemoradiotherapy and
detailed evaluation of treatment effects of adjuvant chemo-
therapy on the basis of selected regimens and of postopera-
tive radiation therapy could not be performed because of
differences in treatment protocols at each individual institu-
tion and a selection bias in which adjuvant therapy may be
applied to patients with more advanced NSCLC. Therefore,
our result could not conclude whether adjuvant therapy was
effective in the Japanese cohort. Well-designed trials on ad-
juvant chemotherapy or chemoradiotherapy for completely
resected stage IIIA NSCLC should be carried out to estab-
lish the significance of adjuvant therapy in the Japanese
cohort.
In conclusion, our study showed that single or multiple
N2 metastases, skip or nonskip N2 metastasis, and pT clas-
sification were independent prognostic factors for DFS,
whereas extent of N2 metastasis, pT classification, tumor
diameter, ECOG PS, and sex were significant prognostic in-
dicators for OS in patients with completely resected pN2
stage IIIA NSCLC. Because the survival benefit of adjuvant
chemotherapy or chemoradiotherapy remains unclear, well-
designed trials on adjuvant therapy for completely resected
stage IIIA NSCLC should be carried out in the Japanese co-
hort, and aforementioned factors, especially pattern of me-
tastasis to N2 regions, should be considered as stratification
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